Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SYHA1801 in Advanced Solid Tumors
NCT04309968Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYHA1801 in solid tumor (advanced stage) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Adverse Events, Serious Adverse Events and Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose at 1 year. Status: unknown.
02
Drugs
SYHA1801
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04309968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309968.